Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction.
Inhibitor formation in haemophilia patients receiving factor VIII (FVIII) concentrate is a serious problem requiring tolerance induction therapy. Inhibitor antibody formation is dependent on interactions between leucocyte cytokines with their corresponding receptors. To investigate this we studied the effect of FVIII on cytokine receptor expression using multiparameter flow cytometry and a whole blood stimulation assay. Upregulation of many cytokine receptors was inhibited by plasma-derived FVIII (pdFVIII) in a dose-dependent manner on T cells, B cells and monocytes although interleukin (IL)-4Ralpha and IL-7Ralpha were upregulated on T cells. The decrease in cytokine receptor upregulation on B cells in the presence of pdFVIII, may result in reduced antibody production. Inhibition of CD132 in the presence of pdFVIII may result in immune tolerance in some recipients of pdFVIII. The immunomodulatory effects of pdFVIII were dose and batch dependent, some being more inhibitory than others. The inhibitory effects of prednisolone with pdFVIII, on cytokine receptor upregulation, were additive. Cytokine receptor expression was not altered in the presence of human recombinant FVIII (rFVIII) concentrate. These findings may explain the reports of less frequent inhibitor antibody formation in some recipients of pdFVIII concentrates. The use of pdFVIII, particularly the more inhibitory batches, may be more suitable than rFVIII for tolerance induction protocols. A clinical study needs to be undertaken to determine the significance of these in vitro findings.
Hodge
G
G
Haematology/Oncology Department, Women's and Children's Hospital, North Adelaide, South Australia, Australia. greg.hodge@cywhs.sa.gov.au
Saxon
B
B
Revesz
T
T
D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000096:biosynthesis; D002478:Cells, Cultured; D003029:Coagulants / Q000276:immunology / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005169:Factor VIII / Q000276:immunology / Q000494:pharmacology*; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007518:Isoantibodies / Q000096:biosynthesis; D007962:Leukocytes / Q000187:drug effects* / Q000276:immunology; D009000:Monocytes / Q000187:drug effects / Q000276:immunology; D011239:Prednisolone / Q000494:pharmacology; D018121:Receptors, Cytokine / Q000187:drug effects* / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects
D019774:Blood Coagulation Factor Inhibitors; D003029:Coagulants; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D018121:Receptors, Cytokine; D011994:Recombinant Proteins; D005169:Factor VIII; D011239:Prednisolone